Transient receptor potential vanilloid 4 channel inhibition attenuates lung ischemia-reperfusion injury in a porcine...

Area of Science:

• Transplantation immunology
• Pulmonary medicine
• Molecular biology

Background:

• Transient receptor potential vanilloid 4 (TRPV4) channels play a role in physiological and pathophysiological processes, including lung disease.
• TRPV4 is implicated in lung ischemia-reperfusion injury, a key factor in primary graft dysfunction post-transplant.
• Previous murine studies demonstrated TRPV4's role in this injury model.

Purpose of the Study:

• To test if a TRPV4 inhibitor can reduce lung ischemia-reperfusion injury in a clinically relevant porcine lung transplant model.
• To evaluate the therapeutic potential of selective TRPV4 inhibition in preventing primary graft dysfunction.

Main Methods:

• A porcine left-lung transplant model was utilized with animals randomized to vehicle or selective TRPV4 inhibitor (GSK2193874) treatment.
• Donor lungs underwent warm ischemia and cold preservation before allotransplantation and reperfusion.
• The TRPV4 inhibitor was administered systemically to recipients post-explant.

Main Results:

• TRPV4 inhibitor treatment significantly improved post-transplant oxygenation.
• Histological lung injury, edema, and neutrophil infiltration were significantly reduced in the inhibitor group.
• Key inflammatory markers (IL-8, HMGB1) and endothelial barrier proteins were favorably modulated by TRPV4 inhibition.

Conclusions:

• TRPV4 inhibition significantly enhances lung function and mitigates ischemia-reperfusion injury in lung transplant recipients.
• Selective TRPV4 inhibition presents a promising therapeutic avenue for preventing primary graft dysfunction.
• Targeting TRPV4 may be a novel strategy to improve outcomes in lung transplantation.